about
Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tractUse of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virusMulti-walled carbon nanotubes increase antibody-producing B cells in mice immunized with a tetravalent vaccine candidate for dengue virusComplexity and Controversies over the Cytokine Profiles of T Helper Cell Subpopulations in TuberculosisHIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategiesMultimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.Vaccines: the Fourth CenturyCurrent progress in the development of therapeutic vaccines for chronic hepatitis B virus infectionAmiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cellsTrypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccineDeletion of parasite immune modulatory sequences combined with immune activating signals enhances vaccine mediated protection against filarial nematodesDNA Vaccine Encoding the Chimeric Form of Schistosoma mansoni Sm-TSP2 and Sm29 Confers Partial Protection against Challenge InfectionIn vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteersRecombinant Salmonella Bacteria Vectoring HIV/AIDS Vaccines.Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6.Novel vaccines to human rabiesAn electrically active microneedle array for electroporation.Immunological properties of gold nanoparticlesProphylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein.Assembly and biological and immunological properties of Newcastle disease virus-like particles.Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal modelsTesting the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs.Nano-biolistics: a method of biolistic transfection of cells and tissues using a gene gun with novel nanometer-sized projectiles.Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in miceEfficient delivery of DNA vaccines using human papillomavirus pseudovirionsIntranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine.A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.Protective immunity induced by Toxoplasma gondii rhoptry protein 16 against toxoplasmosis in mice.Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine.Co-delivery of ccl19 gene enhances anti-caries DNA vaccine pCIA-P immunogenicity in mice by increasing dendritic cell migration to secondary lymphoid tissues.Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality.Venezuelan equine encephalitis virus variants lacking transcription inhibitory functions demonstrate highly attenuated phenotype.Increasing versatility of the DNA vaccines through modification of the subcellular location of plasmid-encoded antigen expression in the in vivo transfected cellsDistinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenzaAdjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGunPreparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles
P2860
Q24610060-3DCAF0A0-A1C8-4C21-BADE-4AC58F7E03E7Q24658311-375B7F21-77FB-4CF7-8E9A-DC70F09EF30CQ26700122-A5FA6C5C-ADC1-4FB8-93A0-35500841DF9BQ26779956-20D1FEC0-8487-4E30-A8A8-CF02F5BB51EFQ26799624-F85FDEEF-FE45-4057-8A85-A716EA709DC7Q27472925-F2C41B8E-B984-4DB7-B2F8-A78BBD5481B8Q27490454-229F2421-94C4-4C8C-B50A-74B739FEF031Q28076279-AAEAE987-A172-428D-997D-5B184BAD8CDFQ28481556-38A92527-31CC-4BBE-9D75-FDB054B2A678Q28483146-E9EA0582-E493-45CD-B3D4-3B75077284BCQ28484629-65BF2AC2-76D0-4F7B-AFF2-3B9DF264035EQ28547011-EC21B60C-6EE4-4D4A-92A7-A606EA5C8573Q28744555-B4A46BEF-D28B-41D8-9018-D4C04FC6ED8BQ30358493-94891B4C-5ED9-4AEA-8F2A-310BB399B4B2Q30415387-5092D320-AFCE-4FFA-A351-43A4F2A93431Q33316774-B3547680-9796-4526-BA45-6572709BE9D2Q33507253-26A1CC82-2033-4FB6-9277-33FCC7F042DAQ33518647-DDF69CDF-FA11-4621-8CAD-80BF8E12113EQ33578950-C40914F6-3880-495B-92D8-E8B4BCC3CF04Q33656471-A009B92D-337D-40B4-A56A-683CC536557BQ33753964-B0294674-3647-415C-A5B8-55BE2C3A709DQ33826688-8CC5050E-6C79-47BE-9CB0-D6B82A6036C0Q33867634-9623F15E-92F1-4DF2-B866-C8D4B052CDA7Q33916310-B0C98DEA-0D8F-4646-A075-E589369C9E87Q33929498-2269A62C-C465-430C-8CA4-358E9EA86C25Q34196487-5EE52DD0-D530-45FA-B417-38F9C071DD82Q34274080-7A9A905B-CC45-4321-8498-D1536989DB3CQ34309830-E966D386-B3B7-47A9-97EE-4F38031FFCE0Q34391647-77520CFA-075A-42FE-803E-AC40B9826E41Q34439869-6F27FA56-5EC0-4777-B2C7-AC40DE149F6FQ34484064-857E66E1-1263-40AA-BB12-76A83F6BB2CDQ34521758-7B5C94B1-B510-40F3-922A-8C96E2D8D0B3Q34555051-E8692EDA-9257-4EF5-981C-0ED8199F343BQ34706913-F4AACE7C-3749-4D97-A4B2-C70C5B2C9B10Q34718486-9240D11D-1BB2-4AD2-A47A-33D90EC56490Q34992691-247CD315-1AED-4574-A532-261E5553BD67Q35018864-79EEE5F7-CACC-49BB-9881-B3F933F0F6B5Q35023393-0C597132-50C0-4DDB-860E-09A5597648A4Q35066456-86ECF928-EA97-4757-AED9-F97B506A4683Q35080032-8909EAC0-26CF-40CE-A065-46D005F24AA3
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
DNA vaccines: progress and challenges.
@ast
DNA vaccines: progress and challenges.
@en
type
label
DNA vaccines: progress and challenges.
@ast
DNA vaccines: progress and challenges.
@en
prefLabel
DNA vaccines: progress and challenges.
@ast
DNA vaccines: progress and challenges.
@en
P1476
DNA vaccines: progress and challenges.
@en
P2093
John J Donnelly
Margaret A Liu
P304
P356
10.4049/JIMMUNOL.175.2.633
P407
P577
2005-07-01T00:00:00Z